# US 2016/0250231 A1 · Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250231 A1
- Document ID: US20160250231A1
- Status: Published application
- Kind: A1
- Application number: 15/154,530
- Filed: 2016-05-13
- Published: 2016-09-01
- Earliest claimed: 2012-02-27
- Assignees: O-Ray Pharma, Inc.
- Applicants: O-Ray Pharma, Inc.
- Inventors: William H. Slattery; Thomas Smith; Erik Pierstorff; Marc M. Baum
- Web page: https://patentgrep.com/patent/US20160250231A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0046: {Ear}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides for pharmaceutical preparations, devices, systems and methods for the treatment of otic diseases and conditions. In various embodiments, the preparations, devices, systems and methods enable sustained drug release for the treatment or prevention of hearing loss, infections, and other pathological conditions of cochlea and inner ear.

## Claims

### Claim 1

A method, comprising:
providing a pharmaceutical preparation for sustained-release of an active pharmaceutical ingredient (API) after cochlear administration or implantation, comprising:
one or more core particles adapted for administration or implantation into the cochlea, wherein each core particle comprises the API, wherein the pharmaceutical preparation is not in a liquid suspension; and
administering or implanting into the cochlea the pharmaceutical preparation to provide sustained-release administration of the API.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein each core particle is one solid API crystal, or wherein each core particle comprises two or more API crystals, and the two or more API crystals are densely packed together.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the API forms a saturated solution within the cochlear fluid after the administering or implanting into the cochlea, and wherein a sustained-release period of the API is determined by the solubility of the API in the cochlear fluid, the turnover of the API from the cochlear fluid, and the amount of the API administered.

### Claim 7 (depends on 1)

The method of claim 1, wherein the one or more core particles are each coated with a first polymeric coating formed from a first polymer-forming solution to form the one or more coated core particles.

### Claim 8 (depends on 7)

The method of claim 7, wherein the API forms a saturated solution within the first polymeric coating after the administering or implanting, and wherein the first polymeric coating is permeable to the API during a sustained-release period from administering the API until the concentration of the API contained within the first polymeric coating is unsaturated.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation comprises 1-15 core particles or coated core particles.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation comprises 1-10 core particles or coated core particles.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation comprises 1-5 core particles or coated core particles.

### Claim 12 (depends on 1)

The method of claim 1, wherein the core particle has a maximum dimension of between 100 μm to 300 μm.

### Claim 13 (depends on 1)

The method of claim 1, wherein the core particle has a maximum diameter of between 150 μm to 250 μm.

### Claim 14 (depends on 1)

The method of claim 1, wherein the core particle has a maximum dimension of between 200 μm to 250 μm.

### Claim 15 (depends on 1)

The method of claim 1, wherein the core particle has a high volume to surface area ratio.

### Claim 16 (depends on 7)

The method of claim 7, wherein diffusion of the API across the first polymeric coating exhibits pseudo-zero-order kinetics during said sustained-release period.

### Claim 17 (depends on 7)

The method of claim 7, wherein the first polymeric coating is substantially degraded after said sustained-release period.

### Claim 18 (depends on 7)

The method of claim 7, wherein the first polymeric coating maintains structural integrity during said sustained-release period.

### Claim 19 (depends on 7)

The method of claim 7, wherein the pharmaceutical preparation comprises 1-15 coated core particles the 1 to 15 coated core particles are administrable to the perilymph via cochlear implantation or injection.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 7)

The method of claim 7, wherein each coated core particle has a maximum dimension between 20 μm and 800 μm

### Claim 23 (depends on 7)

The method of claim 7, wherein each coated core particle has a maximum dimension between 40 μm and 400 μm.

### Claim 24 (depends on 7)

The method of claim 7, wherein each coated core particle has a maximum dimension between 100 μm and 250 μm.

### Claim 25 (depends on 7)

The method of claim 7, wherein the API is substantially insoluble in the first polymer-forming solution.

### Claim 26 (depends on 7)

The method of claim 7, wherein the API is hydrophobic and the first polymer-forming solution is hydrophilic, or wherein the API is hydrophilic and the first polymer-forming solution is hydrophobic.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 7)

The method of claim 7, wherein each coated particle further comprises:
a second polymeric coating on said first polymeric coating, wherein the second polymeric coating is formed from a second polymer-forming solution,
wherein said second polymeric coating is permeable to the API during said sustained-release period; or
a porous second polymeric coating on the first polymeric coating, wherein the porous second polymeric coating is formed from a second polymer-forming solution,
wherein the porous second polymeric coating defines pore regions which permit fluid communication between a pore portion of the first polymeric coating and an external environment, thereby allowing diffusion of the API across the first polymeric coating in the pore regions, and
wherein the porous second polymeric coating defines non-pore regions which prevent fluid communication between a non-pore portion of the first polymeric coating and an external environment, thereby inhibiting diffusion of the API across the first polymeric coating in the non-pore regions.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33 (depends on 7)

The method of claim 7, wherein the first polymeric coating comprises a polymer or co-polymer including at least one monomer selected from the group consisting of sugar phosphates, alkylcellulose, hydroxyalkylcelluloses, lactic acid, glycolic acid, β-propiolactone, β-butyrolactone, γ-butyrolactone, pivalolactone, α-hydroxy butyric acid, α-hydroxyethyl butyric acid, α-hydroxy isovaleric acid, α-hydroxy-β-methyl valeric acid, α-hydroxy caproic acid, α-hydroxy isocaproic acid, α-hydroxy heptanic acid, α-hydroxy octanic acid, α-hydroxy decanoic acid, α-hydroxy myristic acid, α-hydroxy stearic acid, α-hydroxy lignoceric acid, para-xylene, parylene N, halogenated para-xylene, β-phenol lactic acid and polyvinyl alcohol, and the second polymeric coating comprises a polymer or co-polymer including at least one monomer selected from the group consisting of sugar phosphates, alkylcellulose, hydroxyalkylcelluloses, lactic acid, glycolic acid, β-propiolactone, β-butyrolactone, γ-butyrolactone, pivalolactone, α-hydroxy butyric acid, α-hydroxyethyl butyric acid, α-hydroxy isovaleric acid, α-hydroxy-β-methyl valeric acid, α-hydroxy caproic acid, α-hydroxy isocaproic acid, α-hydroxy heptanic acid, α-hydroxy octanic acid, α-hydroxy decanoic acid, α-hydroxy myristic acid, α-hydroxy stearic acid, α-hydroxy lignoceric acid, para-xylene, parylene N, halogenated para-xylene, β-phenol lactic acid and polyvinyl alcohol.

### Claim 34

(canceled)

### Claim 35 (depends on 7)

The method of claim 7, wherein said first polymeric coating is applied to said core particle by an air suspension technique, a dip coating technique, or a vapor deposition technique.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 7)

The method of claim 7, wherein the weight of said first polymeric coating is between 0.001% and 60% of the weight of said core particle, or the volume of said first polymeric coating is between 0.001% and 60% of the volume of said core particle.

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation is administered or implanted by injecting the pharmaceutical preparation through the round window or the oval window for delivery of API into the cochlea.

### Claim 43 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation is administered during a stapedectomy procedure.

### Claim 44 (depends on 1)

The method of claim 1, wherein the method protects against ototoxicity, reduces the risk of sensorineural hearing loss, treats of sensorineural hearing loss, protects against inflammation, treats autoimmune inner ear disease, treats Meniere's disease, reduces the risk of noise induced hearing loss, treats of noise induced hearing loss, treats infection, or treats inner ear vestibular dis-function.

### Claim at position 45

45-91. (canceled)
